Skip to content

Fulgent Genetics

US · FLGT #3667 by market cap Listed 2016
24.12 -0.66 -2.66%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
  • Total institutional ownership fell 1.6 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
56.27% -1.61pp
Institutions
183 +2
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund39.07%
Individual/Insider38.71%
Hedge Fund10.38%
Public Company4.20%
Private Company1.42%
Family Office/Trust0.81%
Government Pension Fund0.25%
Insurance Company0.15%
Other5.01%

Top holders as of 2026-09-01

Ming Hsieh 31.76% · 8.87M sh
BlackRock 8.73% · 2.44M sh
Acadian Asset Management LLC 3.90% · 1.09M sh
Hanlin Gao 3.52% · 984.47K sh
Jacobs Levy Equity Management Inc 2.80% · 782.12K sh
Vanguard Capital Management, LLC 2.74% · 765.87K sh
JPMorgan Chase & Co. 2.61% · 717.22K sh
Diametric Capital, LP 2.50% · 697.78K sh
Columbia Management Investment Advisers, LLC 2.40% · 670.08K sh
Dimensional Fund Advisors 2.31% · 646.63K sh
Jian Xie 2.06% · 576.38K sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 12 buys · 38 sells

NameRoleStake
Ming Hsieh Chairperson & CEO 31.76%
Hanlin Gao Chief Scientific Officer & Lab Director 3.52%
Jian Xie Chief Operating Officer 2.06%
Paul Kim Chief Financial Officer 1.27%
Linda Dong Independent Director 0.04%
Michael Nohaile Independent Director 0.03%
Regina Groves Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-25 Paul Kim Chief Financial Officer Sale to Issuer -2,748 $20.22
2026-10-25 Hanlin Gao Chief Scientific Officer & Lab Director Sale to Issuer -1,645 $20.22
2026-10-25 Jian Xie Chief Operating Officer Sale to Issuer -4,361 $20.22
2026-09-01 Hanlin Gao Chief Scientific Officer & Lab Director Open Market Disposition -1,673 $19.66
2026-09-01 Jian Xie Chief Operating Officer Open Market Disposition -2,127 $19.66
2026-08-31 Paul Kim Chief Financial Officer Sale to Issuer -2,087 $19.59
2026-08-31 Ming Hsieh Chairperson & CEO Sale to Issuer -4,392 $19.59
2026-08-26 Hanlin Gao Chief Scientific Officer & Lab Director Open Market Disposition -939 $19.91
2026-08-26 Jian Xie Chief Operating Officer Open Market Disposition -1,193 $19.91
2026-08-25 Paul Kim Chief Financial Officer Sale to Issuer -1,168 $19.81
2026-08-25 Ming Hsieh Chairperson & CEO Sale to Issuer -2,949 $19.81
2026-07-25 Paul Kim Chief Financial Officer Sale to Issuer -2,747 $19.67
2026-07-25 Hanlin Gao Chief Scientific Officer & Lab Director Sale to Issuer -1,645 $19.67
2026-07-25 Jian Xie Chief Operating Officer Sale to Issuer -4,361 $19.67
2026-06-01 Hanlin Gao Chief Scientific Officer & Lab Director Open Market Disposition -1,688 $17.89
2026-06-01 Jian Xie Chief Operating Officer Open Market Disposition -2,146 $17.89
2026-05-31 Paul Kim Chief Financial Officer Sale to Issuer -2,087 $18.09
2026-05-31 Ming Hsieh Chairperson & CEO Sale to Issuer -4,392 $18.09
2026-05-26 Hanlin Gao Chief Scientific Officer & Lab Director Open Market Disposition -945 $17.60
2026-05-26 Jian Xie Chief Operating Officer Open Market Disposition -1,201 $17.60

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Fulgent Genetics discussion 0 comments

Add a comment